AMC ENTERTAINMENT HOLDINGS, INC. vs Novartis AG — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.41 (market cap $2.14B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 138× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| AMC | NVS | |
|---|---|---|
Market Cap | $2.14B | $295.37B |
Sector | Media | Health |
52-Week High | $3.15 | $168.62 |
52-Week Low | $0.95 | $119.31 |
Enterprise Value | $9.08B | $336.69B |
Dividend Yield | 0.11% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.42, down 6.56% today, yet maintains a bullish technical signal with strong recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by surging attendance and premium screen growth. However, negative net income and substantial debt of $4.01 billion highlight financial strain. Analyst consensus is a $3.00 price target with mixed ratings (32% Buy, 46% Hold).
The outlook hinges on sustained box office recovery and cash flow improvement, with management citing a potential cash-flow breakthrough. Key risks include high leverage, dependence on film slate success, and meme-stock volatility. Upside exists if operational momentum continues, but the negative equity position warrants caution.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →